Market Positioning in RXRX
Recursion Pharmaceuticals (RXRX) has emerged as a primary target for short-selling scrutiny, currently holding the top spot on the Tapeboard squeeze ranking. With 30.8% of its float sold short, the stock is exhibiting classic signs of a crowded trade. The current squeeze score of 90.2 reflects a high-risk environment for short sellers should the stock price experience upward momentum.
Data Breakdown
While the borrow fee remains relatively modest at 0.5%, the high short interest combined with a days-to-cover ratio of 4.9 suggests that any significant buying pressure could force a rapid covering cycle. Investors should note that the stock is currently on the threshold list, indicating persistent failures-to-deliver that often accompany high-conviction short positions. As of the latest data, the market is closely watching for any catalyst that might trigger a short squeeze, given the significant portion of the float currently tied up in bearish bets.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.